Modified experimental vaccine protects monkeys from deadly malaria

May 22, 2017, NIH/National Institute of Allergy and Infectious Diseases
A colorized electron micrograph showing malaria parasite (right, blue) attaching to a human red blood cell. The inset shows a detail of the attachment point at higher magnification. Credit: NIAID

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, modified an experimental malaria vaccine and showed that it completely protected four of eight monkeys that received it against challenge with the virulent Plasmodium falciparum malaria parasite. In three of the remaining four monkeys, the vaccine delayed when parasites first appeared in the blood by more than 25 days.

Malaria symptoms occur when parasites replicate inside red blood cells and cause them to burst. To enter blood cells, the parasite first secretes its own receptor protein, RON2, onto the cell's surface. Another parasite surface protein, AMA1, then binds to a specific portion of RON2, called RON2L, and the resulting complex initiates attachment to the outer membrane of the .

Several experimental malaria vaccines previously tested in people were designed to elicit antibodies against AMA1 and thus prevent from entering . Although AMA1 vaccines did generate high levels of antibodies in humans, they have shown limited efficacy in field trials in malaria-endemic settings.

To improve , the NIAID scientists modified an AMA1 vaccine to include RON2L so that it more closely mimics the protein complex used by the parasite. Monkeys were vaccinated with either AMA1 alone or with the AMA1-RON2L complex vaccine. Although the overall levels of antibodies generated did not differ between the two groups, animals vaccinated with the complex vaccine produced much more neutralizing antibody, indicating a better quality antibody response with AMA1-RON2L vaccination.

Moreover, antibodies taken from AMA1-RON2L-vaccinated monkeys neutralized parasite strains that differed from those used to create the vaccine. This suggests, the authors note, that an AMA1-RON2L complex vaccine could protect against multiple parasite strains. Taken together, the data from this animal study justify progression of this next-generation AMA1 toward possible human trials, they conclude.

Explore further: Vaccine made from complex of two malaria proteins protects mice from lethal infection

More information: Prakash Srinivasan et al, A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection, npj Vaccines (2017). DOI: 10.1038/s41541-017-0015-7

Related Stories

Vaccine made from complex of two malaria proteins protects mice from lethal infection

June 23, 2014
An experimental vaccine designed to spur production of antibodies against a key malaria parasite protein, AMA1, was developed more than decade ago by scientists from the National Institute of Allergy and Infectious Diseases ...

Building a better malaria vaccine: Mixing the right cocktail

December 26, 2013
A safe and effective malaria vaccine is high on the wish list of most people concerned with global health. Results published on December 26 in PLOS Pathogens suggest how a leading vaccine candidate could be vastly improved.

A new target to inhibit malaria and toxoplasmosis infection

July 25, 2011
Maryse Lebrun, Research Director at Inserm, and her fellow researchers at the Laboratoire Dynamique des interactions membranaires normales et pathologiques (CNRS, France), have characterised a protein complex that allows ...

Malaria, toxoplasmosis: Toward new lines of research?

October 10, 2013
A study realized by teams from the Institut Pasteur, the Institut Cochin and the Wellcome Trust Centre for Molecular Parasitology of the University of Glasgow, could redefine part of the present lines of research toward a ...

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.